A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Morphotek

Status and phase: Terminated; Phase 1

Conditions: Melanoma; Advanced Melanoma; Malignant Metastatic Melanoma; Metastatic Melanoma

Treatments: Drug: MORAb-028

Study type: Interventional

Funder types: Industry

Identifiers

NCT01212276

MORAb-028-001

Details and patient eligibility

About

The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.

Full description

Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. Treatment for metastatic melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation therapy. MORAb-028 is a recombinant human immunoglobulin M (IgM) monoclonal antibody that recognizes a cell surface diacyl ganglioside named disialoganglioside (GD2). GD2 is overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas, small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. GD2 expression has been demonstrated in human melanoma and small cell lung cancer by thin layer chromatography and radiolabeled anti-GD2 antibody detection. It is hypothesized that one mode of action of MORAb-028 is complement-dependent cytotoxicity. Complement-dependent cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target cell surface fixes complement, which results in assembly of the complement membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis. IgMs strongly bind to C1Q and robustly activate complement-dependent cytotoxicity. MORAb-028 is being developed as a potential therapy for GD2-positive tumors.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Measurable metastatic melanoma that has failed standard therapy
• Males and females greater than or equal to 18 years of age
• Life expectancy of greater than or equal to 3 months

Exclusion criteria

• Significant cardiovascular impairment
• Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results
• Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 4 patient groups

Cohort 1

Experimental group

Description:

MORAb-028 0.1 mg/kg intravenous

Treatment:

Drug: MORAb-028

Cohort 2

Experimental group

Description:

MORAb-028 0.2 mg/kg intravenous

Treatment:

Drug: MORAb-028

Cohort 3

Experimental group

Description:

MORAb-028 0.5 mg/kg intravenous

Treatment:

Drug: MORAb-028

Cohort 4

Experimental group

Description:

MORAb-028 1.0 mg/kg intravenous

Treatment:

Drug: MORAb-028